Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The ...
BrainStorm Cell Therapeutics (BCLI) secures a $1M private placement at a premium, funding NurOwn ALS Phase 3b and regulatory steps—read the latest update.
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is continuing preparations for the Phase 3b ENDURANCE trial of NurOwn ® for the treatment of patients with amyotrophic lateral sclerosis (ALS). In May ...
Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative ...
) has been revised to $17.34 / share. This is a decrease of 13.95% from the prior estimate of $20.15 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE Post hoc analysis of BCLI's PIII early stage (mild ...
The average one-year price target for Brainstorm Cell Therapeutics (NasdaqCM:BCLI) has been revised to 2.55 / share. This is an increase of 150.00% from the prior estimate of 1.02 dated March 28, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results